RLIP76: A target for kidney cancer therapy

Cancer Research

Volumn 69, Issue 10, 2009, Pages 4244-4251

  Singhal, Sharad S ^a   Singhal, Jyotsana ^a   Yadav, Sushma ^a   Sahu, Mukesh ^a   Awasthi, Yogesh C ^a   Awasthi, Sanjay ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENTARY DNA; PROTEIN DERIVATIVE; RLIP76 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL STRAIN; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN CELL; KIDNEY CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN TARGETING; TUMOR XENOGRAFT;

ANIMALS; ANNEXIN A5; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL SURVIVAL; DNA, ANTISENSE; GLOMERULAR MESANGIUM; GTPASE-ACTIVATING PROTEINS; HUMANS; IN SITU NICK-END LABELING; KIDNEY NEOPLASMS; LIPOSOMES; MICE; MICE, NUDE; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 66249146631     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3521     Document Type: Article

References (52)

1. Eto M, Naito S. Molecular targeting therapy for renal cell carcinoma. Int J Clin Oncol 2006;11:209-213 (Pubitemid 44087119)
2. Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 2007;12:1404-1415
3. Stillebroer AB, Oosterwijk E, Oyen WJ, Mulders PF, Boerman OC. Radio-labeled antibodies in renal cell carcinoma. Cancer Imaging 2007;7:179-188
4. Mellado B, Gascón P. Molecular biology of renal cell carcinoma. Clin Transl Oncol 2006;8:706-710
5. Rutherford EE, Cast JE, Breen DJ. Immediate and long-term CT appearances following radio-frequency ablation of renal tumors. Clin Radiol 2008;63:220-230
6. Bankhead C. Three new drugs available to fight kidney cancer. J Natl Cancer Inst 2006;98:1181-1182
7. Patel PH, Chadalavada RSV, Chaganti, RSK, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006;12:7215-7220 (Pubitemid 46095391)
8. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006;407:597-612.
9. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-930
10. Linehan WM, Vasselli J, Srinivasan R, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004;10:6282-9S. (Pubitemid 39287479)
11. Larkin JM, Eisen T. Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol 2006;60:216-226
12. Robb VA, Karbowniczek M, Klein-Szanto AJ, Henske EP. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 2007;177:346-352
13. Thomas GV. mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev 2006;16:78-84.
14. Panner A, Nakamura JL, Parsa AT, et al. mTOR-independent translational control of the extrinsic cell death pathway by RalA. Mol Cell Biol 2006;26:7345-7357 (Pubitemid 44547688)
15. Gore ME. Temsirolimus in the treatment of advanced renal cell carcinoma. Ann Oncol 2007;18:87-88
16. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281 (Pubitemid 46849157)
17. Huang WC. Is advanced renal cell carcinoma best treated with temsirolimus, interferon α, or both? Nat Clin Pract Oncol 2008;5:16-17
18. Longo R, D'Andrea MR, Sarmiento R, Salerno F, Gasparini G. Integrated therapy of kidney cancer. Ann Oncol 2007;18:141-148
19. Langbein S, Frederiks WM, zur Hausen A, et al. Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int J Cancer 2008;122:2422-2428
20. Pusztai L, Wagner P, Ibrahim N, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005;104:682-691 (Pubitemid 41114904)
21. Modok S, Mellor HR, Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 2006;6:350-354 (Pubitemid 44026037)
22. Shukla S, Wu CP, Ambudkar SV. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol 2008;4:205-223
23. Jullien-Flores V, Dorseuil O, Romero F, et al. Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity. J Biol Chem 1995;270:22473-22477
24. Awasthi S, Cheng J, Singhal SS, et al. Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin. Biochemistry 2000;39:9327-9334 (Pubitemid 30626323)
25. Awasthi S, Singhal SS, Yadav S, et al. RLIP76 is a major determinant of radiation sensitivity. Cancer Res 2005;65:6022-6028 (Pubitemid 40994385)
26. Awasthi S, Singhal SS, Srivastava SK, et al. Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. J Clin Invest 1994;93:958-965 (Pubitemid 2044964)
27. Awasthi S, Singhal SS, Srivastava SK, et al. ATP-dependent human erythrocyte glutathione-conjugate transporter. I. Purification, photoaffinity labeling, and kinetic characteristics of ATPase activity. Biochemistry 1998;37:5231-5238
28. Awasthi S, Singhal SS, Pikula S, et al. ATP-dependent human erythrocyte glutathione-conjugate transporter. II. Functional reconstitution of transport activity. Biochemistry 1998;37:5239-5248
29. Singhal SS, Singhal J, Yadav S, et al. Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (RALBP1). Cancer Res 2007;67:4382-4389
30. Awasthi S, Singhal SS, Sharma R, Zimniak P, Awasthi YC. Transport of glutathione-conjugates and chemotherapeutic drugs by RLIP76: a novel link between Gprotein and tyrosine kinase signaling and drug resistance. Int J Cancer 2003;106:635-646 (Pubitemid 36993386)
31. Singhal SS, Yadav S, Singhal J, Sahu M, Sehrawat A, Awasthi S. Diminished drug transport and augmented radiation sensitivity caused by loss of RLIP76. FEBS Lett 2008;582:3408-3414
32. Sharma R, Singhal, SS, Cheng J, et al. RLIP76 is the major ATP-dependent transporter of glutathione-conjugates and doxorubicin in human erythrocytes. Arch Biochem Biophys 2001;391:171-179 (Pubitemid 32662258)
33. Singhal SS, Yadav S, Roth C, Singhal J. RLIP76: a novel glutathione-conjugate and multi-drug transporter. Biochem Pharmacol 2009;77:761-769
34. Sarkadi B, Homolya L, Szakács G, Váradi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemo-immunity defense system. Physiol Rev 2006;86:1179-1236 (Pubitemid 44521651)
35. Borst P, Evers R, Kool M, Wijnholds J. The multidrug resistance protein family. Biochim Biophys Acta 1999;1461:347-357
36. Singhal J, Singhal SS, Yadav S, et al. RLIP76 in defense of radiation poisoning. Int J Radiat Oncol Biol Phys 2008;72:553-561
37. Awasthi S, Srivastava SK, Ahmad F, Ahmad H, Ansari GA. Interactions of glutathione S-transferase-k with ethacrynic acid and its glutathione conjugate. Biochim Biophys Acta 1993;1164:173-178 (Pubitemid 23211010)
38. Singhal SS, Awasthi YC, Awasthi S. Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res 2006;66:2354-2360 (Pubitemid 43294950)
39. Singhal SS, Yadav S, Drake K, Singhal J, Awasthi S. Hsf-1 and POB1 induce drug-sensitivity and apoptosis by inhibiting Ralbp1. J Biol Chem 2008;283:19714-19729
40. Singhal SS, Singhal J, Sharma R, et al. Role of RLIP76 in lung cancer doxorubicin resistance. I. The ATPase activity of RLIP76 correlates with doxorubicin and 4HNE resistance in lung cancer cells. Int J Oncol 2003;22:365-375
41. Singhal SS, Yadav S, Singhal J, et al. Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. Biochem Pharmacol 2005;70:481-488 (Pubitemid 40905120)
42. Minamide LS, Bamburg JR. A filter paper dye-binding assay for quantitative determination of protein without interference from reducing agents or detergents. Anal Biochem 1990;190:66-70. (Pubitemid 20350131)
43. Hammill AK, Uhr JW, Scheuermann RH. Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Expt Cell Res 1999;251:16-21. (Pubitemid 29406515)
44. Stuckler D, Singhal J, Singhal SS, Yadav S, Awasthi YC, Awasthi S. RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer. Cancer Res 2005;65:991-998 (Pubitemid 40216461)
45. Yadav S, Singhal SS, Singhal J, et al. Identification of membrane anchoring domains of RLIP76 using deletion mutant analyses. Biochemistry 2004;43:16243-16253 (Pubitemid 40041037)
46. Hu Y, Mivechi NF. HSF1 interacts with Ral-binding protein 1 in a stress-responsive, multiprotein complex with HSP90 in vivo. J Biol Chem 2003;278:17299-17306 (Pubitemid 36799613)
47. Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A, Hayakawa M. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res 2004;10:794-801. (Pubitemid 38174018)
48. Sourbier C, Lindner V, Lang H, et al. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 2006;66:5130-5142 (Pubitemid 43844935)
49. Ishitoya S, Kurazono H, Nishiyama H, et al. Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice. J Urol 2004;171:1309-1313 (Pubitemid 38327601)
50. 1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. Clin Cancer Res 2006;12:3470-3477
51. Sourbier C, Danilin S, Lindner V, et al. Targeting the nuclear factor-κB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res 2007;67:11668-11676
52. Sjölund J, Johansson M, Manna S, et al. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest 2008;118:217-228